The Clinical Times
The Front Page of Medicine

Latest medical news

The latest headlines across every section, pulled from official and open-access sources.

MedCity News · Jun 10, 2026

The 5 Areas Where Dr. Oz Says CMS Can Make Healthcare More Affordable

CMS Administrator Dr. Mehmet Oz outlined the agency’s strategy for making healthcare more affordable during a Tuesday address at the HFMA Annual Conference, touching on everything from Medicare fraud to drug pricing to nutrition. The post The 5 Areas Where Dr. Oz Says CMS Can Make Healthcare More Affordable appeared first on MedCity News .

ADA (Diabetes) · Jun 9, 2026

The American Diabetes Association Applauds Maryland for Removing Barriers to Obesity Treatment Coverage

The American Diabetes Association Applauds Maryland for Removing Barriers to Obesity Treatment Coverage mcarmody Tue, 06/09/2026 - 19:38 Advocacy News The American Diabetes Association Applauds Maryland for Removing Barriers to Obesity Treatment Coverage Annapolis, MD June 9, 2026 The American Diabetes Association ® (ADA) applauds the Maryland General Assembly for passing Senate Bill 496 allowing Maryland Medicaid to cover full obesity treatments, including weight-loss medications, if the state chooses to do so, and notifies patients. The strong bipartisan support from the Maryland General…

ACP · Jun 9, 2026

ACP strongly opposed to proposed changes to research funding

Statement attributable to: Jan K. Carney, MD, MPH, MACP President, American College of Physicians WASHINGTON, June 9, 2026—The American College of Physicians (ACP) is deeply concerned about the Office of Management and Budget’s proposed changes to the rules governing federal grants. The proposed rules would direct “senior appointees” at federal agencies to take charge of awarding and terminating new and existing research grants and other federal awards. As an organization with a mission to promote evidence-based medicine, we know the value of independent review by clinical and scientific…

MedCity News · Jun 9, 2026

GSK Gets a Pair of Near-Commercial Lung Cancer Drugs via $10.6B Nuvalent Acquisition

GSK’s Nuvalent acquisition brings two lead programs, each addressing different targets for non-small cell lung cancer. The Nuvalent lung cancer drugs are under FDA review and if they’re approved, GSK plans to launch both this year. The post GSK Gets a Pair of Near-Commercial Lung Cancer Drugs via $10.6B Nuvalent Acquisition appeared first on MedCity News .

FDA Recalls · Jun 9, 2026

Clover Hill Dairy Recalls Soft Ricotta/Requeson Cheese Due to Possible Health Risk

June 5, 2026 - Clover Hill Dairy of Mechanicsville, Maryland is voluntarily recalling all Soft Ricotta/Requeson Cheese because it has the potential to be contaminated with Listeria monocytogenes, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly p

FDA Drugs · Jun 9, 2026

Consumer and Health Care Professional Information

Compounded drugs can serve an important medical need for patients who cannot be treated with an FDA-approved drug, such as a patient who has an allergy and needs a drug to be made without a certain dye, or a child who cannot swallow a tablet or capsule and needs a medicine in a liquid dosage form.

FDA Drugs · Jun 9, 2026

Mitigating Risks of Compounded Drugs Through Surveillance

Mitigating Risks of Compounded Drugs Through Surveillance: The FDA reviews adverse event and product quality reports, and takes action to mitigate identified risks. We also raise awareness about risks related to human drug compounding.

FDA Drugs · Jun 9, 2026

Accelerating Product Development for Pediatric Systemic Lupus Erythematosus (SLE) - 07/30/2026

The U.S. Food and Drug Administration (FDA), with the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), will host a workshop, “Accelerating Product Development for Pediatric Systemic Lupus Erythematosus” on July 30-31, 2026. This workshop will examine key similarities and differences between adult and pedia

FDA Drugs · Jun 9, 2026

Understanding the Risks of Compounded Drugs

Compounded drugs are not FDA-approved. This means the agency does not verify their safety, effectiveness or quality before they are marketed. Learn more.

FDA Drugs · Jun 9, 2026

Compounding Safety Information: Quinacrine Hydrochloride

Quinacrine appears on the FDA 503B list of bulk drug substances that may be used in ccompounded drugs. FDA’s review for the 503B Bulks List determined that there is a clinical need for drug products compounded from quinacrine in the treatment of some patients with cutaneous lupus erythematosus.

ACP · Jun 9, 2026

Internal Medicine Physician and Former ACP President named AMA President-Elect

PHILADELPHIA, June 9, 2026— Former American College of Physicians (ACP) President, Sandra A. Fryhofer, MD, MACP, was elected the American Medical Association (AMA) President-Elect at the AMA House of Delegates Annual Meeting in Chicago earlier today.  Dr. Fryhofer will be AMA President-Elect 2026 to 2027 and will assume the role of AMA President the following year. “Dr. Fryhofer has been a strong advocate for internal medicine, physicians, and our patients for years,” said Jan K. Carney, MD, MPH, president, ACP. “With her background in public health, her work in vaccine advocacy, and her…

Older →

Back to the live front page